Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Jazz Pharmaceuticals Plc - Key Facts

Jazz Pharmaceuticals Plc - Key Employees

Jazz Pharmaceuticals Plc - Key Employee Biographies

Jazz Pharmaceuticals Plc - Major Products and Services

Jazz Pharmaceuticals Plc - History

Jazz Pharmaceuticals Plc - Company Statement

Jazz Pharmaceuticals Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Jazz Pharmaceuticals Plc - Business Description

Product Category: Defitelio/defibrotide

Overview

Performance

Product Category: Erwinaze/Erwinase

Overview

Performance

Product Category: Other

Overview

Product Category: Other Products

Performance

Product Category: Prialt (ziconotide) Intrathecal Infusion

Overview

Performance

Product Category: Vyxeos

Overview

Performance

Product Category: Xyrem

Overview

Performance

Product Category: Net Product Sales

Performance

Product Category: Royalties and Contract Revenue

Performance

Geographical Segment: All Other

Performance

Geographical Segment: Europe

Performance

Geographical Segment: The US

Performance

R&D Overview

Jazz Pharmaceuticals Plc - Corporate Strategy

Jazz Pharmaceuticals Plc - SWOT Analysis

SWOT Analysis - Overview

Jazz Pharmaceuticals Plc - Strengths

Jazz Pharmaceuticals Plc - Weaknesses

Jazz Pharmaceuticals Plc - Opportunities

Jazz Pharmaceuticals Plc - Threats

Jazz Pharmaceuticals Plc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Jazz Pharmaceuticals Plc, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 07, 2019: Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results

Apr 08, 2019: Jazz, Alexion and Lundbeck to pay $122m to settle kickback probe

Feb 26, 2019: Jazz Pharmaceuticals announces full year and fourth quarter 2018 financial results

Feb 14, 2019: Jazz Pharmaceuticals announces appointment of Anne O'Riordan to its board of directors

Jan 04, 2019: Jazz and Codiak collaborate on creating engineered exosomes for cancer

Nov 09, 2018: Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea

Nov 06, 2018: Jazz Pharmaceuticals announces third quarter 2018 financial results

Oct 29, 2018: Jazz Pharmaceuticals Announces FDA Approval of Xyrem (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Oct 08, 2018: Jazz Pharmaceuticals Undergoes Drug supply Shortage Due to Manufacturing Problems

Oct 01, 2018: Jazz Pharmaceuticals Survey Highlights Significant Impact of Excessive Daytime Sleepiness Related to Sleep Apnea

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Jazz Pharmaceuticals Plc (JAZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc Key Recent Developments

May 07,2019 Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results
Apr 08,2019 Jazz, Alexion and Lundbeck to pay $122m to settle kickback probe
Feb 26,2019 Jazz Pharmaceuticals announces full year and fourth quarter 2018 financial results
Feb 14,2019 Jazz Pharmaceuticals announces appointment of Anne O'Riordan to its board of directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company